File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Bone marrow stem cell therapy for myocardial angiogenesis

TitleBone marrow stem cell therapy for myocardial angiogenesis
Authors
Issue Date2007
PublisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cvp/index.htm
Citation
Current Vascular Pharmacology, 2007, v. 5 n. 2, p. 103-112 How to Cite?
AbstractDespite the recent advances in medical therapy and coronary revascularization procedures, coronary artery disease (CAD) remains the major cause of morbidity and mortality in the developing countries. In patients with severe CAD, persistent myocardial ischemia in hibernated myocardium resulted in progressive loss of cardiomyocytes with development of heart failure. As a result, therapeutic approaches to enhance neovascularization are being underwent intensive investigation. Recent experimental studies have demonstrated adult bone marrow (BM) can induce neovascularization in ischemic myocardium can improve heart function. These findings have prompted the development of different cellular transplantation approaches for heart diseases refractory to conventional therapy after myocardial infarction. Although the initial pilot clinical trials have shown potential clinical benefit of BM therapy for therapeutic angiogenesis, the long-term safety, the optimal timing and treatment strategy remains unclear. Furthermore, in order to acquire more optimized quality and quantity of BM derived stem cell for myocardial regeneration, several issues remain to be addressed, such as the development of a more efficient method of stem cells identification, purification and expansion. Emerging, rationally designed, randomized clinical trials are required to assess the clinical implication of of BM derived stem cells therapy in treatment of CAD. © 2007 Bentham Science Publishers Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/76341
ISSN
2015 Impact Factor: 2.374
2015 SCImago Journal Rankings: 0.839
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTse, HFen_HK
dc.contributor.authorYiu, KHen_HK
dc.contributor.authorLau, CPen_HK
dc.date.accessioned2010-09-06T07:20:12Z-
dc.date.available2010-09-06T07:20:12Z-
dc.date.issued2007en_HK
dc.identifier.citationCurrent Vascular Pharmacology, 2007, v. 5 n. 2, p. 103-112en_HK
dc.identifier.issn1570-1611en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76341-
dc.description.abstractDespite the recent advances in medical therapy and coronary revascularization procedures, coronary artery disease (CAD) remains the major cause of morbidity and mortality in the developing countries. In patients with severe CAD, persistent myocardial ischemia in hibernated myocardium resulted in progressive loss of cardiomyocytes with development of heart failure. As a result, therapeutic approaches to enhance neovascularization are being underwent intensive investigation. Recent experimental studies have demonstrated adult bone marrow (BM) can induce neovascularization in ischemic myocardium can improve heart function. These findings have prompted the development of different cellular transplantation approaches for heart diseases refractory to conventional therapy after myocardial infarction. Although the initial pilot clinical trials have shown potential clinical benefit of BM therapy for therapeutic angiogenesis, the long-term safety, the optimal timing and treatment strategy remains unclear. Furthermore, in order to acquire more optimized quality and quantity of BM derived stem cell for myocardial regeneration, several issues remain to be addressed, such as the development of a more efficient method of stem cells identification, purification and expansion. Emerging, rationally designed, randomized clinical trials are required to assess the clinical implication of of BM derived stem cells therapy in treatment of CAD. © 2007 Bentham Science Publishers Ltd.en_HK
dc.languageengen_HK
dc.publisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cvp/index.htmen_HK
dc.relation.ispartofCurrent Vascular Pharmacologyen_HK
dc.subject.meshAnimalsen_HK
dc.subject.meshBone Marrow Cells - physiologyen_HK
dc.subject.meshBone Marrow Transplantation - physiologyen_HK
dc.subject.meshCardiomyopathies - therapyen_HK
dc.subject.meshCoronary Artery Disease - pathology - therapyen_HK
dc.subject.meshCytokines - therapeutic useen_HK
dc.subject.meshHematopoietic Stem Cell Mobilizationen_HK
dc.subject.meshHumansen_HK
dc.subject.meshNeovascularization, Pathologic - therapyen_HK
dc.subject.meshStem Cells - physiologyen_HK
dc.titleBone marrow stem cell therapy for myocardial angiogenesisen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1570-1611&volume=5&issue=2&spage=103&epage=12&date=2007&atitle=Bone+marrow+stem+cell+therapy+for+myocardial+angiogenesisen_HK
dc.identifier.emailTse, HF:hftse@hkucc.hku.hken_HK
dc.identifier.emailYiu, KH:khkyiu@hku.hken_HK
dc.identifier.authorityTse, HF=rp00428en_HK
dc.identifier.authorityYiu, KH=rp01490en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.2174/157016107780368299en_HK
dc.identifier.pmid17430214-
dc.identifier.scopuseid_2-s2.0-34247882004en_HK
dc.identifier.hkuros126514en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-34247882004&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume5en_HK
dc.identifier.issue2en_HK
dc.identifier.spage103en_HK
dc.identifier.epage112en_HK
dc.identifier.isiWOS:000244879700002-
dc.publisher.placeNetherlandsen_HK
dc.identifier.scopusauthoridTse, HF=7006070805en_HK
dc.identifier.scopusauthoridYiu, KH=35172267800en_HK
dc.identifier.scopusauthoridLau, CP=7401968501en_HK
dc.identifier.citeulike1214244-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats